Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Csernok

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
Journal of Leukocyte Biology|February 24, 2001
Subthreshold concentrations of anti-proteinase 3 antibodies (c-ANCA) specifically prime human neutrophils for fMLP-induced leukotriene synthesis and chemotaxisK Hattar, U Sibelius, A Bickenbach, et al.
The Journal of Rheumatology|August 26, 1998
Elevated procalcitonin levels in active Wegener's granulomatosisF Moosig, E Csernok, E Reinhold-Keller, et al.
Immunitat Und Infektion|February 1, 1991
[Distribution pattern of proteinase 3 in Wegener's granulomatosis and other vasculitic diseases]M G Braun, E Csernok, H K Müller-Hermelink, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Treatment of Wegener's granulomatosis with intravenous immunoglobulinC Richter, A Schnabel, E Csernok, et al.
Annals of the Rheumatic Diseases|April 22, 2005
Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?J U Holle, B Hellmich, M Backes, et al.
The American Journal of Pathology|October 1, 1991
Proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener's granulomatosis. Immunolocalization in normal and pathologic tissuesM G Braun, E Csernok, W L Gross, et al.
Arthritis and Rheumatism|May 1, 1995
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significanceA Schnabel, E Csernok, D A Isenberg, et al.
Arthritis and Rheumatism|September 1, 1992
Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activityW H Schmitt, C Heesen, E Csernok, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Treatment modalities and ANCA in Takayasu's arteritisM Schwarz-Eywill, A Breitbart, E Csernok, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA)W H Schmitt, E Csernok, B K Flesch, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Journal of Leukocyte Biology|February 24, 2001
Subthreshold concentrations of anti-proteinase 3 antibodies (c-ANCA) specifically prime human neutrophils for fMLP-induced leukotriene synthesis and chemotaxisK Hattar, U Sibelius, A Bickenbach, et al.
The Journal of Rheumatology|August 26, 1998
Elevated procalcitonin levels in active Wegener's granulomatosisF Moosig, E Csernok, E Reinhold-Keller, et al.
Immunitat Und Infektion|February 1, 1991
[Distribution pattern of proteinase 3 in Wegener's granulomatosis and other vasculitic diseases]M G Braun, E Csernok, H K Müller-Hermelink, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Treatment of Wegener's granulomatosis with intravenous immunoglobulinC Richter, A Schnabel, E Csernok, et al.
Annals of the Rheumatic Diseases|April 22, 2005
Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?J U Holle, B Hellmich, M Backes, et al.
The American Journal of Pathology|October 1, 1991
Proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener's granulomatosis. Immunolocalization in normal and pathologic tissuesM G Braun, E Csernok, W L Gross, et al.
Arthritis and Rheumatism|May 1, 1995
Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significanceA Schnabel, E Csernok, D A Isenberg, et al.
Arthritis and Rheumatism|September 1, 1992
Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activityW H Schmitt, C Heesen, E Csernok, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Treatment modalities and ANCA in Takayasu's arteritisM Schwarz-Eywill, A Breitbart, E Csernok, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA)W H Schmitt, E Csernok, B K Flesch, et al.
Pageof 11